 | • レポートコード：MRC2102QY15837 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、130ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界のワクチン用粒子状アジュバント市場について種類別（経口、皮下、鼻腔内、筋肉内、皮内、その他）、用途別（感染症、癌、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・ワクチン用粒子状アジュバント市場の概要 ・世界の主要地域別ワクチン用粒子状アジュバント市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界のワクチン用粒子状アジュバント市場規模2015-2026：種類別（経口、皮下、鼻腔内、筋肉内、皮内、その他） ・世界のワクチン用粒子状アジュバント市場規模2015-2026：用途別（感染症、癌、その他） ・ワクチン用粒子状アジュバントの米国市場規模2015-2020 ・ワクチン用粒子状アジュバントのヨーロッパ市場規模2015-2020 ・ワクチン用粒子状アジュバントの中国市場規模2015-2020 ・ワクチン用粒子状アジュバントの日本市場規模2015-2020 ・ワクチン用粒子状アジュバントの東南アジア市場規模2015-2020 ・ワクチン用粒子状アジュバントのインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・ワクチン用粒子状アジュバントの製造コスト分析 ・販売チャネル、流通業者、顧客 ・ワクチン用粒子状アジュバントの市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Vaccine Particulate Adjuvants Market
The global Vaccine Particulate Adjuvants market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Vaccine Particulate Adjuvants Scope and Market Size
The global Vaccine Particulate Adjuvants market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Vaccine Particulate Adjuvants market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Vaccine Particulate Adjuvants market is segmented into
Oral
Subcutaneous
Intranasal
Intramuscular
Intradermal
Others
Segment by Application, the Vaccine Particulate Adjuvants market is segmented into
Infectious Diseases
Cancer
Others
The Vaccine Particulate Adjuvants market is analysed and market size information is provided by regions (countries). Segment by Application, the Vaccine Particulate Adjuvants market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Vaccine Particulate Adjuvants Market Share Analysis
Vaccine Particulate Adjuvants market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Vaccine Particulate Adjuvants business, the date to enter into the Vaccine Particulate Adjuvants market, Vaccine Particulate Adjuvants product introduction, recent developments, etc.
The major vendors covered:
Brenntag Biosector (Denmark)
CSL Limited (Australia)
SEPPIC (France)
Agenus, Inc (US)
Novavax, Inc (US)
SPI Pharma, Inc (US)
Invivogen (US)
Avanti Polar Lipids, Inc (US)
MVP Laboratories, Inc (US)
OZ Biosciences (France)
1 Vaccine Particulate Adjuvants Market Overview
1.1 Vaccine Particulate Adjuvants Product Scope
1.2 Vaccine Particulate Adjuvants Segment by Type
1.2.1 Global Vaccine Particulate Adjuvants Sales by Type (2020-2026)
1.2.2 Oral
1.2.3 Subcutaneous
1.2.4 Intranasal
1.2.5 Intramuscular
1.2.6 Intradermal
1.2.7 Others
1.3 Vaccine Particulate Adjuvants Segment by Application
1.3.1 Global Vaccine Particulate Adjuvants Sales Comparison by Application (2020-2026)
1.3.2 Infectious Diseases
1.3.3 Cancer
1.3.4 Others
1.4 Vaccine Particulate Adjuvants Market Estimates and Forecasts (2015-2026)
1.4.1 Global Vaccine Particulate Adjuvants Sales Growth Rate (2015-2026)
1.4.2 Global Vaccine Particulate Adjuvants Revenue and Growth Rate (2015-2026)
1.4.3 Global Vaccine Particulate Adjuvants Price Trends (2015-2026)
2 Vaccine Particulate Adjuvants Estimate and Forecast by Region
2.1 Global Vaccine Particulate Adjuvants Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Vaccine Particulate Adjuvants Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Vaccine Particulate Adjuvants Sales Market Share by Region (2015-2020)
2.2.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Region (2015-2020)
2.3 Global Vaccine Particulate Adjuvants Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Vaccine Particulate Adjuvants Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Vaccine Particulate Adjuvants Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Vaccine Particulate Adjuvants Estimates and Projections (2015-2026)
2.4.2 Europe Vaccine Particulate Adjuvants Estimates and Projections (2015-2026)
2.4.3 China Vaccine Particulate Adjuvants Estimates and Projections (2015-2026)
2.4.4 Japan Vaccine Particulate Adjuvants Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Vaccine Particulate Adjuvants Estimates and Projections (2015-2026)
2.4.6 India Vaccine Particulate Adjuvants Estimates and Projections (2015-2026)
3 Global Vaccine Particulate Adjuvants Competition Landscape by Players
3.1 Global Top Vaccine Particulate Adjuvants Players by Sales (2015-2020)
3.2 Global Top Vaccine Particulate Adjuvants Players by Revenue (2015-2020)
3.3 Global Vaccine Particulate Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vaccine Particulate Adjuvants as of 2019)
3.4 Global Vaccine Particulate Adjuvants Average Price by Company (2015-2020)
3.5 Manufacturers Vaccine Particulate Adjuvants Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Vaccine Particulate Adjuvants Players (Opinion Leaders)
4 Global Vaccine Particulate Adjuvants Market Size by Type
4.1 Global Vaccine Particulate Adjuvants Historic Market Review by Type (2015-2020)
4.1.1 Global Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
4.1.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Type (2015-2020)
4.1.3 Global Vaccine Particulate Adjuvants Price by Type (2015-2020)
4.2 Global Vaccine Particulate Adjuvants Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Vaccine Particulate Adjuvants Sales Forecast by Type (2021-2026)
4.2.2 Global Vaccine Particulate Adjuvants Revenue Forecast by Type (2021-2026)
4.2.3 Global Vaccine Particulate Adjuvants Price Forecast by Type (2021-2026)
5 Global Vaccine Particulate Adjuvants Market Size by Application
5.1 Global Vaccine Particulate Adjuvants Historic Market Review by Application (2015-2020)
5.1.1 Global Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
5.1.2 Global Vaccine Particulate Adjuvants Revenue Market Share by Application (2015-2020)
5.1.3 Global Vaccine Particulate Adjuvants Price by Application (2015-2020)
5.2 Global Vaccine Particulate Adjuvants Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Vaccine Particulate Adjuvants Sales Forecast by Application (2021-2026)
5.2.2 Global Vaccine Particulate Adjuvants Revenue Forecast by Application (2021-2026)
5.2.3 Global Vaccine Particulate Adjuvants Price Forecast by Application (2021-2026)
6 United States Vaccine Particulate Adjuvants Market Facts & Figures
6.1 United States Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
6.2 United States Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
6.3 United States Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
7 Europe Vaccine Particulate Adjuvants Market Facts & Figures
7.1 Europe Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
7.2 Europe Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
7.3 Europe Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
8 China Vaccine Particulate Adjuvants Market Facts & Figures
8.1 China Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
8.2 China Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
8.3 China Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
9 Japan Vaccine Particulate Adjuvants Market Facts & Figures
9.1 Japan Vaccine Particulate Adjuvants Sales Market Share by Company (3015-3030)
9.2 Japan Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
9.3 Japan Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
10 Southeast Asia Vaccine Particulate Adjuvants Market Facts & Figures
10.1 Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
11 India Vaccine Particulate Adjuvants Market Facts & Figures
11.1 India Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
11.2 India Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
11.3 India Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Vaccine Particulate Adjuvants Business
12.1 Brenntag Biosector (Denmark)
12.1.1 Brenntag Biosector (Denmark) Corporation Information
12.1.2 Brenntag Biosector (Denmark) Business Overview
12.1.3 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Products Offered
12.1.5 Brenntag Biosector (Denmark) Recent Development
12.2 CSL Limited (Australia)
12.2.1 CSL Limited (Australia) Corporation Information
12.2.2 CSL Limited (Australia) Business Overview
12.2.3 CSL Limited (Australia) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.2.4 CSL Limited (Australia) Vaccine Particulate Adjuvants Products Offered
12.2.5 CSL Limited (Australia) Recent Development
12.3 SEPPIC (France)
12.3.1 SEPPIC (France) Corporation Information
12.3.2 SEPPIC (France) Business Overview
12.3.3 SEPPIC (France) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.3.4 SEPPIC (France) Vaccine Particulate Adjuvants Products Offered
12.3.5 SEPPIC (France) Recent Development
12.4 Agenus, Inc (US)
12.4.1 Agenus, Inc (US) Corporation Information
12.4.2 Agenus, Inc (US) Business Overview
12.4.3 Agenus, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Agenus, Inc (US) Vaccine Particulate Adjuvants Products Offered
12.4.5 Agenus, Inc (US) Recent Development
12.5 Novavax, Inc (US)
12.5.1 Novavax, Inc (US) Corporation Information
12.5.2 Novavax, Inc (US) Business Overview
12.5.3 Novavax, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Novavax, Inc (US) Vaccine Particulate Adjuvants Products Offered
12.5.5 Novavax, Inc (US) Recent Development
12.6 SPI Pharma, Inc (US)
12.6.1 SPI Pharma, Inc (US) Corporation Information
12.6.2 SPI Pharma, Inc (US) Business Overview
12.6.3 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.6.4 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Products Offered
12.6.5 SPI Pharma, Inc (US) Recent Development
12.7 Invivogen (US)
12.7.1 Invivogen (US) Corporation Information
12.7.2 Invivogen (US) Business Overview
12.7.3 Invivogen (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Invivogen (US) Vaccine Particulate Adjuvants Products Offered
12.7.5 Invivogen (US) Recent Development
12.8 Avanti Polar Lipids, Inc (US)
12.8.1 Avanti Polar Lipids, Inc (US) Corporation Information
12.8.2 Avanti Polar Lipids, Inc (US) Business Overview
12.8.3 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Products Offered
12.8.5 Avanti Polar Lipids, Inc (US) Recent Development
12.9 MVP Laboratories, Inc (US)
12.9.1 MVP Laboratories, Inc (US) Corporation Information
12.9.2 MVP Laboratories, Inc (US) Business Overview
12.9.3 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.9.4 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Products Offered
12.9.5 MVP Laboratories, Inc (US) Recent Development
12.10 OZ Biosciences (France)
12.10.1 OZ Biosciences (France) Corporation Information
12.10.2 OZ Biosciences (France) Business Overview
12.10.3 OZ Biosciences (France) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2015-2020)
12.10.4 OZ Biosciences (France) Vaccine Particulate Adjuvants Products Offered
12.10.5 OZ Biosciences (France) Recent Development
13 Vaccine Particulate Adjuvants Manufacturing Cost Analysis
13.1 Vaccine Particulate Adjuvants Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Vaccine Particulate Adjuvants
13.4 Vaccine Particulate Adjuvants Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Vaccine Particulate Adjuvants Distributors List
14.3 Vaccine Particulate Adjuvants Customers
15 Market Dynamics
15.1 Vaccine Particulate Adjuvants Market Trends
15.2 Vaccine Particulate Adjuvants Opportunities and Drivers
15.3 Vaccine Particulate Adjuvants Market Challenges
15.4 Vaccine Particulate Adjuvants Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Vaccine Particulate Adjuvants Sales (K Pcs) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Vaccine Particulate Adjuvants Sales (K Pcs) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Vaccine Particulate Adjuvants Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Region (2015-2020)
Table 5. Global Vaccine Particulate Adjuvants Sales Market Share by Region (2015-2020)
Table 6. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Vaccine Particulate Adjuvants Revenue Share by Region (2015-2020)
Table 8. Global Vaccine Particulate Adjuvants Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Vaccine Particulate Adjuvants Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Vaccine Particulate Adjuvants Revenue Share Forecast by Region (2021-2026)
Table 12. Global Vaccine Particulate Adjuvants (K Pcs) of Key Companies (2015-2020)
Table 13. Global Vaccine Particulate Adjuvants Sales Share by Company (2015-2020)
Table 14. Global Vaccine Particulate Adjuvants Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Vaccine Particulate Adjuvants Revenue Share by Company (2015-2020)
Table 16. Global Vaccine Particulate Adjuvants by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Vaccine Particulate Adjuvants as of 2019)
Table 17. Global Vaccine Particulate Adjuvants Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Vaccine Particulate Adjuvants Manufacturing Sites and Area Served
Table 19. Manufacturers Vaccine Particulate Adjuvants Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Vaccine Particulate Adjuvants Players
Table 22. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2015-2020)
Table 23. Global Vaccine Particulate Adjuvants Sales Share by Type (2015-2020)
Table 24. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Vaccine Particulate Adjuvants Price (K Pcs) by Type (2015-2020)
Table 26. Global Vaccine Particulate Adjuvants Sales Share by Type (2021-2026)
Table 27. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Vaccine Particulate Adjuvants Revenue Share by Type (2021-2026)
Table 29. Global Vaccine Particulate Adjuvants Price (K Pcs) by Type (2021-2026)
Table 30. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2015-2020)
Table 31. Global Vaccine Particulate Adjuvants Sales Share by Application (2015-2020)
Table 32. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Vaccine Particulate Adjuvants Price (K Pcs) by Application (2015-2020)
Table 34. Global Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2021-2026)
Table 35. Global Vaccine Particulate Adjuvants Sales Share by Application (2021-2026)
Table 36. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Vaccine Particulate Adjuvants Revenue Share by Application (2021-2026)
Table 38. Global Vaccine Particulate Adjuvants Price (K Pcs) by Application (2021-2026)
Table 39. United States Vaccine Particulate Adjuvants Sales (K Pcs) by Company (2015-2020)
Table 40. United States Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
Table 41. United States Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2015-2020)
Table 42. United States Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
Table 43. United States Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2015-2020)
Table 44. United States Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
Table 45. Europe Vaccine Particulate Adjuvants Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
Table 47. Europe Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
Table 49. Europe Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
Table 51. China Vaccine Particulate Adjuvants Sales (K Pcs) by Company (2015-2020)
Table 52. China Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
Table 53. China Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2015-2020)
Table 54. China Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
Table 55. China Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2015-2020)
Table 56. China Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
Table 57. Japan Vaccine Particulate Adjuvants Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
Table 59. Japan Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
Table 61. Japan Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Vaccine Particulate Adjuvants Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
Table 69. India Vaccine Particulate Adjuvants Sales (K Pcs) by Company (2015-2020)
Table 70. India Vaccine Particulate Adjuvants Sales Market Share by Company (2015-2020)
Table 71. India Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2015-2020)
Table 72. India Vaccine Particulate Adjuvants Sales Market Share by Type (2015-2020)
Table 73. India Vaccine Particulate Adjuvants Sales (K Pcs) by Application (2015-2020)
Table 74. India Vaccine Particulate Adjuvants Sales Market Share by Application (2015-2020)
Table 75. Brenntag Biosector (Denmark) Corporation Information
Table 76. Brenntag Biosector (Denmark) Description and Business Overview
Table 77. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product
Table 79. Brenntag Biosector (Denmark) Recent Development
Table 80. CSL Limited (Australia) Corporation Information
Table 81. CSL Limited (Australia) Description and Business Overview
Table 82. CSL Limited (Australia) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. CSL Limited (Australia) Vaccine Particulate Adjuvants Product
Table 84. CSL Limited (Australia) Recent Development
Table 85. SEPPIC (France) Corporation Information
Table 86. SEPPIC (France) Description and Business Overview
Table 87. SEPPIC (France) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. SEPPIC (France) Vaccine Particulate Adjuvants Product
Table 89. SEPPIC (France) Recent Development
Table 90. Agenus, Inc (US) Corporation Information
Table 91. Agenus, Inc (US) Description and Business Overview
Table 92. Agenus, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Agenus, Inc (US) Vaccine Particulate Adjuvants Product
Table 94. Agenus, Inc (US) Recent Development
Table 95. Novavax, Inc (US) Corporation Information
Table 96. Novavax, Inc (US) Description and Business Overview
Table 97. Novavax, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Novavax, Inc (US) Vaccine Particulate Adjuvants Product
Table 99. Novavax, Inc (US) Recent Development
Table 100. SPI Pharma, Inc (US) Corporation Information
Table 101. SPI Pharma, Inc (US) Description and Business Overview
Table 102. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Product
Table 104. SPI Pharma, Inc (US) Recent Development
Table 105. Invivogen (US) Corporation Information
Table 106. Invivogen (US) Description and Business Overview
Table 107. Invivogen (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Invivogen (US) Vaccine Particulate Adjuvants Product
Table 109. Invivogen (US) Recent Development
Table 110. Avanti Polar Lipids, Inc (US) Corporation Information
Table 111. Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Avanti Polar Lipids, Inc (US) Description and Business Overview
Table 113. Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Product
Table 114. Avanti Polar Lipids, Inc (US) Recent Development
Table 115. MVP Laboratories, Inc (US) Corporation Information
Table 116. MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. MVP Laboratories, Inc (US) Description and Business Overview
Table 118. MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Product
Table 119. MVP Laboratories, Inc (US) Recent Development
Table 120. OZ Biosciences (France) Corporation Information
Table 121. OZ Biosciences (France) Description and Business Overview
Table 122. OZ Biosciences (France) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. OZ Biosciences (France) Vaccine Particulate Adjuvants Product
Table 124. OZ Biosciences (France) Recent Development
Table 125. Production Base and Market Concentration Rate of Raw Material
Table 126. Key Suppliers of Raw Materials
Table 127. Vaccine Particulate Adjuvants Distributors List
Table 128. Vaccine Particulate Adjuvants Customers List
Table 129. Vaccine Particulate Adjuvants Market Key Trends
Table 130. Vaccine Particulate Adjuvants Key Opportunities and Drivers
Table 131. Vaccine Particulate Adjuvants Market Challenges
Table 132. Research Programs/Design for This Report
Table 133. Key Data Information from Secondary Sources
Table 134. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine Particulate Adjuvants Product Picture
Figure 2. Global Vaccine Particulate Adjuvants Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Vaccine Particulate Adjuvants Market Share by Application in 2020 & 2026
Figure 6. Infectious Diseases Examples
Figure 7. Cancer Examples
Figure 8. Others Examples
Figure 9. Global Vaccine Particulate Adjuvants Sales (K Pcs) Growth Rate (2015-2026)
Figure 10. Global Vaccine Particulate Adjuvants Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Vaccine Particulate Adjuvants Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 12. Global Vaccine Particulate Adjuvants Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Vaccine Particulate Adjuvants Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Vaccine Particulate Adjuvants Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Vaccine Particulate Adjuvants Sales (K Pcs) Growth Rate (2015-2026)
Figure 16. Europe Vaccine Particulate Adjuvants Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Vaccine Particulate Adjuvants Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Vaccine Particulate Adjuvants Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Vaccine Particulate Adjuvants Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Vaccine Particulate Adjuvants Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Vaccine Particulate Adjuvants Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Vaccine Particulate Adjuvants Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Vaccine Particulate Adjuvants Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Vaccine Particulate Adjuvants Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Vaccine Particulate Adjuvants Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Vaccine Particulate Adjuvants Players Market Share by Revenue in Vaccine Particulate Adjuvants 2015 & 2019
Figure 27. Vaccine Particulate Adjuvants Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Vaccine Particulate Adjuvants Revenue Share by Type (2015-2020)
Figure 29. Global Vaccine Particulate Adjuvants Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Vaccine Particulate Adjuvants Revenue Share by Application (2015-2020)
Figure 31. Global Vaccine Particulate Adjuvants Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Vaccine Particulate Adjuvants Sales Market Share by Type in 2019
Figure 33. United States Vaccine Particulate Adjuvants Sales Market Share by Type in 2019
Figure 34. Europe Vaccine Particulate Adjuvants Sales Market Share by Company in 2019
Figure 35. Europe Vaccine Particulate Adjuvants Sales Market Share by Type in 2019
Figure 36. Europe Vaccine Particulate Adjuvants Sales Market Share by Application in 2019
Figure 37. China Vaccine Particulate Adjuvants Sales Market Share by Company in 2019
Figure 38. China Vaccine Particulate Adjuvants Sales Market Share by Type in 2019
Figure 39. China Vaccine Particulate Adjuvants Sales Market Share by Application in 2019
Figure 40. Japan Vaccine Particulate Adjuvants Sales Market Share by Company in 2019
Figure 41. Japan Vaccine Particulate Adjuvants Sales Market Share by Type in 2019
Figure 42. Japan Vaccine Particulate Adjuvants Sales Market Share by Application in 2019
Figure 43. Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Company in 2019
Figure 44. Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Type in 2019
Figure 45. Southeast Asia Vaccine Particulate Adjuvants Sales Market Share by Application in 2019
Figure 46. India Vaccine Particulate Adjuvants Sales Market Share by Company in 2019
Figure 47. India Vaccine Particulate Adjuvants Sales Market Share by Type in 2019
Figure 48. India Vaccine Particulate Adjuvants Sales Market Share by Application in 2019
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Vaccine Particulate Adjuvants
Figure 51. Manufacturing Process Analysis of Vaccine Particulate Adjuvants
Figure 52. Vaccine Particulate Adjuvants Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Porter's Five Forces Analysis
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
獣医用ワクチンアジュバントの世界市場レポート2020 An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities. And many vacci…- ワクチンアジュバントの世界市場レポート2020 An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been …
- ガソリンパティキュレートフィルター（GPF）の世界市場レポート2020 Gasoline particulate filters (GPF) are used to remove particulate matter from the exhaust gas from a gasoline direct injection (GDI) engine. A GDI engine has a higher emission of particulate matter than a port fuel injection gasoline engine. GPF controls the particulate emission by trapping the part…
- 粒子状呼吸器の世界市場レポート2020 A respirator is a device designed to protect the wearer from inhaling harmful dusts, fumes, vapors, or gases. Respirators come in a wide range of types and sizes used by the military, private industry, and the public. Respirators range from relatively inexpensive single-use, disposable masks to more…
- 乗用車用ガソリンパティキュレートフィルターの世界市場レポート2020 Gasoline particulate filters (GPF) are an emission aftertreatment technology based on diesel particulate filters (DPF), developed to control particulate emissions from gasoline direct injection (GDI) engines. The industry's leading producers are Corning, NGK Insulators and Faurecia, with revenues of…